Table 1.
Clinical Features at Diagnosis
| No. of patients | 65 |
| Male, n (%) | 32 (49.2) |
| Median age, years (absolute range/IR) |
75.1 (65.0-89.3/70.5-78.7) |
| Sokal risk: n (%) | |
| Low | 3 (4.6) |
| Intermediate | 39 (60.0) |
| High | 20 (30.8) |
| Not evaluable | 3 (4.6) |
| Performance status (ECOG), n (%) | |
| Grade 0-1 | 55 (84.6%) |
| Grade 2 | 10 (15.4%) |
| Median Hb, g/dl (IR) |
12.5 (11.4-13.8) |
| Median white blood cell count, ×109/l (IR) |
48.3 (27.8-93.7) |
| Median PLTs, ×109/l (IR) |
430 (243-803) |
| Spleen enlargement, cm below costal margin (%) | |
| 0 | 37 (57.0) |
| 1-5 | 22 (33.8) |
| > 5 | 5 (7.7) |
| Not evaluable | 1 (1.5) |
| Most common comorbidities, n (%): | |
| Arterial hypertension | 37 (56.9) |
| Diabetes | 14 (21.5) |
| Dyslipidemia | 13 (20.0) |
| Cardiovascular diseases | 10 (15.3) |
| Previous/concomitant neoplasia | 10 (15.3) |
ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; PLTs, platelets.